Cloud-Clone expands antibody platform for research and diagnostics

By AI, Created 9:37 AM UTC, May 20, 2026, /AGP/ – Cloud-Clone Corp. says it has built an integrated antibody R&D and manufacturing platform aimed at improving product consistency, scalable production and cross-platform use. The move targets long-standing antibody quality problems that can affect research reproducibility and diagnostic development.

Why it matters: - Antibodies are core tools in life science research and key raw materials for in vitro diagnostics. - Better consistency and batch stability can improve experimental reproducibility, assay reliability and development timelines. - Broader cross-platform compatibility can make the same reagents more useful across research and diagnostic workflows.

What happened: - Cloud-Clone Corp. said it has developed an integrated antibody development and manufacturing platform for research and diagnostic applications. - The platform is designed to improve product consistency, scalable production and cross-platform usability. - The company framed the effort as a response to quality variability and production challenges across the antibody market.

The details: - Cloud-Clone said the platform covers antigen design, recombinant protein expression, antibody preparation, purification and validation. - The company operates peptide synthesis, small-molecule antigen modification, native protein extraction, recombinant protein expression systems and SPF-grade animal facilities. - Cloud-Clone has expanded recombinant antibody technologies alongside conventional antibody development methods. - The company said recombinant production helps reduce variability tied to unstable cell lines and fluctuating yields while improving lot-to-lot consistency. - Cloud-Clone offers monoclonal antibodies, polyclonal antibodies and recombinant antibodies for research and industrial use. - The company said its quality system includes raw material controls, production oversight and finished-product testing. - Antigens go through purity analysis and characterization testing before production. - Automated workflows are used in antibody expression, purification and labeling. - Finished products are tested under internal quality standards for reproducibility and stable batch-to-batch performance. - Cloud-Clone’s quality systems are certified under ISO9001 and ISO13485. - The company says its products are used by research institutions, biotechnology companies and diagnostic developers in international markets. - Cloud-Clone’s portfolio is built for life science research, in vitro diagnostics, veterinary medicine and food safety testing. - The portfolio supports Western blotting, immunohistochemistry, immunofluorescence, ELISA and flow cytometry. - Certain products can detect analytes at the picogram level. - Labeling options include biotin, HRP and FITC. - The company says more than 27,000 antibody products cover oncology, immunology, neuroscience, metabolism, infectious diseases and other research areas. - Cloud-Clone says its antibodies have supported studies in immunology, cancer biology, inflammatory disease and cell signaling. - The company says its products have been cited in more than 16,000 SCI-indexed publications. - CiteAb recognized Cloud-Clone in the ELISA reagent category. - In diagnostics, the antibodies are used for infectious disease testing, tumor marker detection, autoimmune disease research, biomarker assay development, veterinary diagnostics and food safety monitoring. - Cloud-Clone also works with universities, laboratories, distributors and research organizations through technical workshops, scientific exhibitions and application support programs. - The company’s technical teams help with experimental optimization, product selection and assay development. - Cloud-Clone said its products have been used in research laboratories in Russia.

Between the lines: - The company is positioning itself as both a reagent maker and a technical partner, not just a supplier. - Emphasis on recombinant antibodies, automation and certified quality systems suggests a push to reduce one of the sector’s biggest pain points: variability. - The mix of research, IVD, veterinary and food-safety use cases shows an effort to spread risk across multiple end markets.

What’s next: - Cloud-Clone plans to expand its antibody development platforms and application support capabilities. - The company says it will keep focusing on consistency, cross-platform compatibility and support for precision medicine and diagnostic development. - More information is available in the company’s announcement.

The bottom line: - Cloud-Clone is betting that tighter quality control and broader assay compatibility will help its antibody business scale across research and diagnostics.